Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 200.29

0.0%

Jan 8 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: dwc who wrote (19195)	4/17/1998 9:36:00 PM
From: Henry Niman	of 32384

09/21/95 MERRILL LYNCH CAPITAL MARKETS Ligand has a unique technology advantage: intracellular receptors as targets for small molecule drugs. Existing intracellular receptor (IR) targeted drugs already command a $5 billion annual worldwide market but have significant limitations that Ligand's technology could overcome. Five drug company partners in the development of IR compounds and two in a new technology, STATS, help validate Ligand's technology and management as well as manage cash burn rate. Allergan Ligand Retinoid Therapeutics (ALRT), a $100 million off-balance sheet entity, is a driver of near term products. Early clinical trial results in cancer with two compounds, LGD1069 and ALRT1057 topically in AIDS related Kaposi's sarcoma and cutaneous T-cell lymphoma are expected soon.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next